Opinion
Video
William J. Gradishar, MD, analyzes current guidelines for identifying targetable mutations in breast cancer, explores strategies to enhance biomarker testing for mutations like PIK3CA or AKT1, and anticipates the growing influence of personalized medicine on the future of breast cancer treatment.